ARTICLE | Product Development
High fidelity
How Wave's nucleic acid technology could confer an advantage in Huntington's
February 15, 2016 8:00 AM UTC
Wave Life Sciences Ltd. has set its sights on rare neuromuscular and CNS diseases where its stereopure nucleic acid technology could confer safety and efficacy advantages over competing programs.
Wave was formed in 2012 from the merger of Ontorii Inc. and Chiralgen Ltd. Since 2009 the predecessor companies had been optimizing technologies to design and manufacture stereopure nucleic acids...